169 related articles for article (PubMed ID: 12627672)
1. Thrombolytic therapy: clinical applications.
Baker WF
Hematol Oncol Clin North Am; 2003 Feb; 17(1):283-311. PubMed ID: 12627672
[TBL] [Abstract][Full Text] [Related]
2. Thrombolytic therapy.
Baker WF
Clin Appl Thromb Hemost; 2002 Oct; 8(4):291-314. PubMed ID: 12516680
[TBL] [Abstract][Full Text] [Related]
3. Translational initiatives in thrombolytic therapy.
Klegerman ME
Front Med; 2017 Mar; 11(1):1-19. PubMed ID: 28116631
[TBL] [Abstract][Full Text] [Related]
4. New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.
Maksimenko AV; Tischenko EG
J Thromb Thrombolysis; 1999 Jun; 7(3):307-12. PubMed ID: 10373713
[TBL] [Abstract][Full Text] [Related]
5. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
6. Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.
Marder VJ
Thromb Res; 2009; 123 Suppl 4():S56-61. PubMed ID: 19303506
[TBL] [Abstract][Full Text] [Related]
7. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
8. Benefits of Long Versus Short Thrombolysis Times for Acutely Thrombosed Hemodialysis Native Fistulas.
Regus S; Lang W; Heinz M; Uder M; Schmid A
Vasc Endovascular Surg; 2017 Jul; 51(5):233-239. PubMed ID: 28639916
[TBL] [Abstract][Full Text] [Related]
9. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis.
Skeik N; Gits CC; Ehrenwald E; Cragg AH
Vasc Endovascular Surg; 2013 Oct; 47(7):519-23. PubMed ID: 23899656
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Anti-Tissue Type Plasminogen Activator Antibodies in Patients With Prosthetic Heart Valve Thrombosis: The ATA Trial.
Özkan M; Kalçık M; Gürsoy MO; Öcal L; Griffini S; Karakoyun S; Yesin M; Gündüz S; Astarcıoğlu MA; Bayam E; Cerşit S; Aykan AÇ; Cugno M
J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):372-80. PubMed ID: 26657322
[TBL] [Abstract][Full Text] [Related]
12. New developments in thrombolytic therapy.
Collen DC; Gold HK
Thromb Res Suppl; 1990; 10():105-31. PubMed ID: 2180114
[TBL] [Abstract][Full Text] [Related]
13. Newer thrombolytic drugs for acute myocardial infarction.
Reddy DS
Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
[TBL] [Abstract][Full Text] [Related]
14. [Catheter-guided thrombolysis in peripheral arterial occlusion].
Lindholt JS; Holt G; Sandermann J
Ugeskr Laeger; 2001 Nov; 163(48):6734-8. PubMed ID: 11768897
[TBL] [Abstract][Full Text] [Related]
15. New thrombolytic agents and strategies.
Collen D; Lijnen HR
Baillieres Clin Haematol; 1995 Jun; 8(2):425-35. PubMed ID: 7549072
[TBL] [Abstract][Full Text] [Related]
16. [Development of new thrombolytic substances].
Zeymer U; Neuhaus KL
Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
[TBL] [Abstract][Full Text] [Related]
17. Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial.
Özkan M; Gündüz S; Biteker M; Astarcioglu MA; Çevik C; Kaynak E; Yıldız M; Oğuz E; Aykan AÇ; Ertürk E; Karavelioğlu Y; Gökdeniz T; Kaya H; Gürsoy OM; Çakal B; Karakoyun S; Duran N; Özdemir N
JACC Cardiovasc Imaging; 2013 Feb; 6(2):206-16. PubMed ID: 23489534
[TBL] [Abstract][Full Text] [Related]
18. [Thrombolytic agents, urokinase, tissue-type plasminogen activator and pro-urokinase--their routes of administration and dosage: comparison between intracoronary thrombolysis and intravenous coronary thrombolysis].
Motomiya T
Nihon Rinsho; 2003 Apr; 61 Suppl 4():441-5. PubMed ID: 12735012
[No Abstract] [Full Text] [Related]
19. The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk.
Gardell SJ
Toxicol Pathol; 1993; 21(2):190-8. PubMed ID: 8210941
[TBL] [Abstract][Full Text] [Related]
20. Successful thrombolysis of left subclavian arterial thrombosis with intravenous bolus dose of tenecteplase.
Akkala R; Mallempalli S; Kuchulakanti PK
Indian Heart J; 2017; 69(1):101-103. PubMed ID: 28228289
[No Abstract] [Full Text] [Related]
[Next] [New Search]
